NRAS and Noonan syndrome: Remarkably, the LM cluster was enriched for patients known to have low-risk disease26, including all patients diagnosed with Noonan syndrome and MPD (18, 100%), all JMML patients carrying CBL mutations (13) and the majority of patients with NRAS mutations (14/19, 73.7%; Fig. 2).